Across TCGA pan-cancer cohorts, EIF3C mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EIF3C data layer compared with 21 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EIF3C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF3C expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where EIF3C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.616	0.879	<.001	21	view →
HNSC	DFS	Median	II,III,IV	0.761	0.544	.005	11	view →
PDAC	OS	Median	II,III,IV	0.943	0.730	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: EIF3C tumor-vs-normal RNA expression · all EIF3C data types